HEALTHWDIV CLICKONDETROIT
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA's upcoming panel to review controversial peptide drugs includes health professionals with financial ties to the industry, including clinics and pharmacies promoting unproven peptides. The meeting follows concerns about the safety and regulatory status of substances like BPC-157 and TB-500, which are marketed for wellness purposes but lack scientific validation. Health Secretary Robert F. Kennedy Jr. has publicly supported these peptides.
Mentioned
Related Signal
Adjacent reporting
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
- STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
- FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures
- FDA to weigh lifting restrictions on some MAHA-favored peptides